down arrow

Emergent BioSolutions, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US29089Q1058
USD
12.05
0.45 (3.88%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

11.5212.28

52 Week

4.0213.41
Valuation
Technical
Day's Volume

CASH

1.12 M

Shareholding (Mar 2025)

FII

12.98%

Held by 98 FIIs

DII

48.94%

Held by 44 DIIs

Promoter

0.03%

How big is Emergent BioSolutions, Inc.?

22-Jun-2025

As of Jun 18, Emergent BioSolutions, Inc. has a market capitalization of 345.07 million, with net sales of 965.40 million and a net profit of -131.60 million over the latest four quarters.

Market Cap: As of Jun 18, Emergent BioSolutions, Inc. has a market capitalization of 345.07 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Emergent BioSolutions reported net sales of 965.40 million and a net profit of -131.60 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 482.80 million and total assets of 1,396.90 million.

Read More

What does Emergent BioSolutions, Inc. do?

22-Jun-2025

Emergent BioSolutions, Inc. is a life sciences company focused on developing medical countermeasures for public health threats, with a market cap of $345.07 million and quarterly net sales of $222 million as of March 2025. Key financial metrics include a debt-to-equity ratio of 0.93 and a return on equity of -15.10%.

Overview: <BR>Emergent BioSolutions, Inc. is a life sciences company in the Pharmaceuticals & Biotechnology industry, focusing on developing medical countermeasures for public health threats.<BR><BR>Financial Snapshot: <BR>Net Sales: 222 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 68 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 345.07 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 0.93 <BR>Return on Equity: -15.10% <BR>Price to Book: 0.62<BR><BR>Contact Details: <BR>Address: 400 Professional Dr Ste 400, GAITHERSBURG MD: 20879-3457 <BR>Tel: ['1 240 6313200', '1 240 6313280'] <BR>Fax: 1 240 6313203 <BR>Website: https://emergentbiosolutions.com/

Read More

Who are in the management team of Emergent BioSolutions, Inc.?

22-Jun-2025

As of March 2022, the management team of Emergent BioSolutions, Inc. includes Executive Chairman Fuad El-Hibri, President and CEO Robert Kramer, Lead Independent Director Ronald Richard, and Directors Seamus Mulligan, Marvin White, Independent Directors Sue Bailey and Zsolt Harsanyi. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Emergent BioSolutions, Inc. includes the following individuals:<BR><BR>- Mr. Fuad El-Hibri, who serves as the Executive Chairman of the Board.<BR>- Mr. Robert Kramer, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Ronald Richard, who holds the position of Lead Independent Director.<BR>- Mr. Seamus Mulligan, who is a Director.<BR>- Mr. Marvin White, who is also a Director.<BR>- Dr. Sue Bailey, who serves as an Independent Director.<BR>- Dr. Zsolt Harsanyi, who is another Independent Director. <BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Read More

Is Emergent BioSolutions, Inc. overvalued or undervalued?

20-Sep-2025

As of August 6, 2025, Emergent BioSolutions, Inc. has improved from a risky to an attractive valuation grade, indicating it may be undervalued with a current price of $7.94, a Price to Book Value of 0.67, and an EV to EBITDA of 14.99, suggesting potential for recovery and growth compared to its peers.

As of 6 August 2025, the valuation grade for Emergent BioSolutions, Inc. has moved from risky to attractive, indicating a significant improvement in its investment appeal. The company appears to be undervalued, especially when considering its Price to Book Value of 0.67, EV to Sales ratio of 0.91, and EV to EBITDA of 14.99. In comparison, peers such as Fusion Pharmaceuticals, Inc. exhibit a risky valuation with an EV to EBITDA of -15.5851, while Rigel Pharmaceuticals, Inc. is rated very attractive with an EV to EBITDA of 6.4016.<BR><BR>Despite the lack of return data for the company, its recent valuation change suggests a positive outlook compared to the broader market. The current price of $7.94, alongside a notable 52-week high of $12.73, reinforces the notion that the stock may be positioned for recovery and growth.

Read More

Is Emergent BioSolutions, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Emergent BioSolutions, Inc. shows a bullish technical trend with strong weekly indicators, despite mixed monthly signals and underperformance compared to the S&P 500 over the past year.

As of 31 October 2025, the technical trend for Emergent BioSolutions, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and daily moving averages also indicate a bullish stance. However, the monthly MACD remains mildly bullish, and the KST shows a mixed signal with weekly bullishness and monthly mild bearishness. Bollinger Bands are mildly bullish on both weekly and monthly time frames. The stock has performed well recently, with a 1-week return of 4.13% compared to the S&P 500's 0.71%, but it lags behind the benchmark over longer periods, with a 1-year return of 10.64% versus 19.89% for the S&P 500. Overall, the current technical stance is bullish, supported by strong weekly indicators, despite some mixed signals on the monthly charts.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate -16.76% of over the last 5 years

 
2

Positive results in Jun 25

3

With ROE of -15.10%, it has a risky valuation with a 0.67 Price to Book Value

4

Market Beating Performance

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 412 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.74

stock-summary
Return on Equity

26.51%

stock-summary
Price to Book

0.77

Revenue and Profits:
Net Sales:
141 Million
(Quarterly Results - Jun 2025)
Net Profit:
-12 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
57.93%
0%
57.93%
6 Months
90.36%
0%
90.36%
1 Year
27.78%
0%
27.78%
2 Years
368.87%
0%
368.87%
3 Years
0.42%
0%
0.42%
4 Years
-71.23%
0%
-71.23%
5 Years
-85.45%
0%
-85.45%

Emergent BioSolutions, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Emergent BioSolutions, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Emergent BioSolutions, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and daily moving averages also indicate a bullish stance. However, the monthly MACD remains mildly bullish, and the KST shows a mixed signal with weekly bullishness and monthly mild bearishness. Bollinger Bands are mildly bullish on both weekly and monthly time frames. The stock has performed well recently, with a 1-week return of 4.13% compared to the S&P 500's 0.71%, but it lags behind the benchmark over longer periods, with a 1-year return of 10.64% versus 19.89% for the S&P 500. Overall, the current technical stance is bullish, supported by strong weekly indicators, despite some mixed signals on the monthly charts....

Read More

Is Emergent BioSolutions, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Emergent BioSolutions, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. The daily moving averages also reflect a bullish stance. However, the KST is mildly bearish on a monthly basis, and the Dow Theory shows a mildly bullish trend for both weekly and monthly periods. Overall, the strength of the bullish signal is supported by the daily moving averages and the weekly MACD. There is no available return data for comparison with the S&P 500....

Read More

Is Emergent BioSolutions, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Emergent BioSolutions, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and daily moving averages. The monthly MACD is mildly bullish, while the KST shows a mixed signal with a mildly bearish stance. The Dow Theory indicates a mildly bullish trend on both weekly and monthly time frames. In terms of performance, the stock has outperformed the S&P 500 significantly over the past week (28.13% vs. 0.71%) and month (35.80% vs. 1.92%), but has underperformed over longer periods, including the past three years and five years. Overall, the current stance is bullish with strong short-term momentum....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-7.53%
EBIT Growth (5y)
-16.76%
EBIT to Interest (avg)
4.18
Debt to EBITDA (avg)
4.15
Net Debt to Equity (avg)
0.93
Sales to Capital Employed (avg)
0.74
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
87.29%
ROCE (avg)
9.11%
ROE (avg)
7.50%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.67
EV to EBIT
-17.79
EV to EBITDA
14.99
EV to Capital Employed
0.83
EV to Sales
0.91
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4.65%
ROE (Latest)
-15.10%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 54 Schemes (37.98%)

Foreign Institutions

Held by 98 Foreign Institutions (12.98%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -36.59% vs 14.12% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -117.65% vs 317.25% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "140.90",
          "val2": "222.20",
          "chgp": "-36.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "24.50",
          "val2": "74.60",
          "chgp": "-67.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "14.70",
          "val2": "14.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.10",
          "val2": "1.30",
          "chgp": "-15.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.00",
          "val2": "68.00",
          "chgp": "-117.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "3.50%",
          "val2": "218.70%",
          "chgp": "-21.52%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -0.54% vs -6.10% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 74.94% vs -259.40% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,043.60",
          "val2": "1,049.30",
          "chgp": "-0.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "53.60",
          "val2": "-42.90",
          "chgp": "224.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "71.00",
          "val2": "96.80",
          "chgp": "-26.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-50.30",
          "val2": "-554.40",
          "chgp": "90.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-190.60",
          "val2": "-760.50",
          "chgp": "74.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-56.00%",
          "val2": "-163.90%",
          "chgp": "10.79%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
140.90
222.20
-36.59%
Operating Profit (PBDIT) excl Other Income
24.50
74.60
-67.16%
Interest
14.70
14.70
Exceptional Items
1.10
1.30
-15.38%
Consolidate Net Profit
-12.00
68.00
-117.65%
Operating Profit Margin (Excl OI)
3.50%
218.70%
-21.52%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -36.59% vs 14.12% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -117.65% vs 317.25% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,043.60
1,049.30
-0.54%
Operating Profit (PBDIT) excl Other Income
53.60
-42.90
224.94%
Interest
71.00
96.80
-26.65%
Exceptional Items
-50.30
-554.40
90.93%
Consolidate Net Profit
-190.60
-760.50
74.94%
Operating Profit Margin (Excl OI)
-56.00%
-163.90%
10.79%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -0.54% vs -6.10% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 74.94% vs -259.40% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Emergent BioSolutions, Inc. stock-summary
stock-summary
Emergent BioSolutions, Inc.
Pharmaceuticals & Biotechnology
Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
Company Coordinates stock-summary
Company Details
400 Professional Dr Ste 400 , GAITHERSBURG MD : 20879-3457
stock-summary
Tel: 1 240 63132001 240 6313280
stock-summary
https://emergentbiosolutions.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."